;PMID: 11510629 ;source_file_1896.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..38] = [t:0..38] ;1)sentence:[e:44..117] = [t:44..117] ;2)section:[e:121..171] = [t:121..171] ;3)section:[e:175..245] = [t:175..245] ;4)sentence:[e:249..422] = [t:249..422] ;5)sentence:[e:423..560] = [t:423..560] ;6)sentence:[e:562..653] = [t:562..653] ;7)sentence:[e:654..850] = [t:654..850] ;8)sentence:[e:851..998] = [t:851..998] ;9)sentence:[e:999..1146] = [t:999..1146] ;10)sentence:[e:1147..1307] = [t:1147..1307] ;11)sentence:[e:1308..1406] = [t:1308..1406] ;12)sentence:[e:1407..1662] = [t:1407..1662] ;13)sentence:[e:1663..1786] = [t:1663..1786] ;14)sentence:[e:1787..1900] = [t:1787..1900] ;15)sentence:[e:1902..2000] = [t:1902..2000] ;16)sentence:[e:2001..2139] = [t:2001..2139] ;17)section:[e:2143..2161] = [t:2143..2161] ;18)section:[e:2167..2173] = [t:2167..2173] ;19)section:[e:2179..2195] = [t:2179..2195] ;20)section:[e:2199..2244] = [t:2199..2244] ;section 0 Span:0..38 ;Clin Pharmacokinet. 2001;40(7):523-37. (SEC (FRAG (NNP:[0..4] Clin) (NNP:[5..18] Pharmacokinet) (.:[18..19] .) (CD:[20..24] 2001) (CC:[24..27] ;40) (-LRB-:[27..28] -LRB-) (CD:[28..29] 7) (-RRB-:[29..30] -RRB-) (::[30..31] :) (CD:[31..37] 523-37) (.:[37..38] .))) ;sentence 1 Span:44..117 ;Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. ;[44..48]:substance:"Drug" ;[74..86]:substance:"esomeprazole" ;[92..102]:substance:"(S)-isomer" ;[106..116]:substance:"omeprazole" (SENT (NP-HLN (NP (NML (NN:[44..48] Drug) (NN:[49..60] interaction)) (NNS:[61..68] studies)) (PP (IN:[69..73] with) (NP (NP (NN:[74..86] esomeprazole)) (,:[86..87] ,) (NP (NP (DT:[88..91] the) (NN:[92..102] -LRB-S-RRB--isomer)) (PP (IN:[103..105] of) (NP (NN:[106..116] omeprazole)))))) (.:[116..117] .))) ;section 2 Span:121..171 ;Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. (SEC (FRAG (NNP:[121..130] Andersson) (NNP:[131..132] T) (,:[132..133] ,) (NNP:[134..140] Hassan) (HYPH:[140..141] -) (NNP:[141..145] Alin) (NNP:[146..148] M,) (NNP:[149..159] Hasselgren) (NNP:[160..161] G) (,:[161..162] ,) (NNP:[163..168] Rohss) (NNP:[169..171] K.))) ;section 3 Span:175..245 ;Clinical Pharmacology, AstraZeneca LP, Wayne, Pennsylvania 19087, USA. (SEC (FRAG (NNP:[175..183] Clinical) (NNP:[184..196] Pharmacology) (,:[196..197] ,) (NNP:[198..209] AstraZeneca) (NNP:[210..212] LP) (,:[212..213] ,) (NNP:[214..219] Wayne) (,:[219..220] ,) (NNP:[221..233] Pennsylvania) (CD:[234..239] 19087) (,:[239..240] ,) (NNP:[241..244] USA) (.:[244..245] .))) ;sentence 4 Span:249..422 ;Esomeprazole, the (S)-isomer of omeprazole, is the first proton pump ;inhibitor (PPI) developed as a single isomer for the treatment of patients ;with acid related diseases. ;[249..261]:substance:"Esomeprazole" ;[267..277]:substance:"(S)-isomer" ;[281..291]:substance:"omeprazole" ;[306..327]:substance:"proton pump inhibitor" ;[330..333]:substance:"PPI" ;[357..363]:substance:"isomer" ;[399..403]:substance:"acid" (SENT (S (NP-SBJ (NP (NN:[249..261] Esomeprazole)) (,:[261..262] ,) (NP (NP (DT:[263..266] the) (NN:[267..277] -LRB-S-RRB--isomer)) (PP (IN:[278..280] of) (NP (NN:[281..291] omeprazole))))) (,:[291..292] ,) (VP (VBZ:[293..295] is) (NP-PRD (NP (NP (DT:[296..299] the) (JJ:[300..305] first) (NML (NN:[306..312] proton) (NN:[313..317] pump)) (NN:[318..327] inhibitor)) (NP (-LRB-:[329..330] -LRB-) (NN:[330..333] PPI) (-RRB-:[333..334] -RRB-))) (VP (VBN:[335..344] developed) (NP (-NONE-:[344..344] *)) (PP (IN:[345..347] as) (NP (DT:[348..349] a) (JJ:[350..356] single) (NN:[357..363] isomer))) (PP-PRP (IN:[364..367] for) (NP (NP (DT:[368..371] the) (NN:[372..381] treatment)) (PP (IN:[382..384] of) (NP (NP (NNS:[385..393] patients)) (PP (IN:[394..398] with) (NP (ADJP (NN:[399..403] acid) (VBN:[405..412] related)) (NNS:[413..421] diseases)))))))))) (.:[421..422] .))) ;sentence 5 Span:423..560 ;Because of the extensive use of PPIs, the documentation of the potential for ;drug interactions with esomeprazole is of great importance. ;[455..459]:substance:"PPIs" ;[501..505]:substance:"drug" ;[524..536]:substance:"esomeprazole" (SENT (S (PP (IN:[423..430] Because) (IN:[431..433] of) (NP (NP (DT:[434..437] the) (JJ:[438..447] extensive) (NN:[448..451] use)) (PP (IN:[452..454] of) (NP (NNS:[455..459] PPIs))))) (,:[459..460] ,) (NP-SBJ (NP (DT:[461..464] the) (NN:[465..478] documentation)) (PP (IN:[479..481] of) (NP (NP (DT:[482..485] the) (NN:[487..496] potential)) (PP (IN:[497..500] for) (NP (NP (NN:[501..505] drug) (NNS:[506..518] interactions)) (PP (IN:[519..523] with) (NP (NN:[524..536] esomeprazole)))))))) (VP (VBZ:[537..539] is) (PP-PRD (IN:[540..542] of) (NP (JJ:[543..548] great) (NN:[549..559] importance)))) (.:[559..560] .))) ;sentence 6 Span:562..653 ;Altered absorption or metabolism are 2 of the major mechanisms for drug-drug ;interactions. ;[629..633]:substance:"drug" ;[634..638]:substance:"drug" (SENT (S (NP-SBJ (NP (ADJP-1 (VBN:[562..569] Altered)) (NN:[570..580] absorption)) (CC:[581..583] or) (NP (ADJP-1 (-NONE-:[583..583] *P*)) (NN:[584..594] metabolism))) (VP (VBP:[595..598] are) (NP-PRD (NP (CD:[599..600] 2)) (PP (IN:[601..603] of) (NP (NP (DT:[604..607] the) (JJ:[608..613] major) (NNS:[614..624] mechanisms)) (PP (IN:[625..628] for) (NP (NML (NN:[629..633] drug) (HYPH:[633..634] -) (NN:[634..638] drug)) (NNS:[640..652] interactions))))))) (.:[652..653] .))) ;sentence 7 Span:654..850 ;Since intragastric pH will increase with esomeprazole treatment, it can be ;hypothesised that the absorption of drugs with pH-sensitive absorption (e.g. ;digoxin and ketoconazole) may be affected. ;[695..707]:substance:"esomeprazole" ;[766..771]:substance:"drugs" ;[808..815]:substance:"digoxin" ;[820..832]:substance:"ketoconazole" (SENT (S (SBAR-ADV (IN:[654..659] Since) (S (NP-SBJ (JJ:[660..672] intragastric) (NN:[673..675] pH)) (VP (MD:[676..680] will) (VP (VB:[681..689] increase) (PP (IN:[690..694] with) (NP (NN:[695..707] esomeprazole) (NN:[708..717] treatment))))))) (,:[717..718] ,) (NP-SBJ-2 (NP (PRP:[720..722] it)) (SBAR-3 (-NONE-:[722..722] *EXP*))) (VP (MD:[723..726] can) (VP (VB:[727..729] be) (VP (VBN:[730..742] hypothesised) (NP-2 (-NONE-:[742..742] *)) (SBAR-3 (IN:[743..747] that) (S (NP-SBJ-1 (NP (DT:[748..751] the) (NN:[752..762] absorption)) (PP (IN:[763..765] of) (NP (NP (NNS:[766..771] drugs)) (PP (IN:[772..776] with) (NP (ADJP (NN:[777..779] pH) (HYPH:[779..780] -) (JJ:[780..789] sensitive)) (NN:[790..800] absorption))) (PRN (-LRB-:[802..803] -LRB-) (NP (ADVP (FW:[803..807] e.g.)) (NN:[808..815] digoxin) (CC:[816..819] and) (NN:[820..832] ketoconazole)) (-RRB-:[832..833] -RRB-))))) (VP (MD:[834..837] may) (VP (VB:[838..840] be) (VP (VBN:[841..849] affected) (NP-1 (-NONE-:[849..849] *)))))))))) (.:[849..850] .))) ;sentence 8 Span:851..998 ;Esomeprazole does not seem to have any potential to interact with drugs that ;are metabolised by cytochrome P450 (CYP) 1 A2, 2A6, 2C9, 2D6 or 2E1. ;[851..863]:substance:"Esomeprazole" ;[918..923]:substance:"drugs" ;[948..975]:cyp450:"cytochrome P450 (CYP) 1 A2" ;[948..970]...[994..997]:cyp450:"cytochrome P450 (CYP)"..."2E1" ;[948..970]...[987..990]:cyp450:"cytochrome P450 (CYP)"..."2D6" ;[948..970]...[982..985]:cyp450:"cytochrome P450 (CYP)"..."2C9" ;[948..970]...[977..980]:cyp450:"cytochrome P450 (CYP)"..."2A6" (SENT (S (NP-SBJ-4 (NN:[851..863] Esomeprazole)) (VP (VBZ:[864..868] does) (RB:[869..872] not) (VP (VB:[873..877] seem) (S (NP-SBJ-4 (-NONE-:[877..877] *)) (VP (TO:[878..880] to) (VP (VB:[882..886] have) (NP (DT:[887..890] any) (NN:[891..900] potential) (S (NP-SBJ (-NONE-:[900..900] *)) (VP (TO:[901..903] to) (VP (VB:[904..912] interact) (PP-CLR (IN:[913..917] with) (NP (NP (NNS:[918..923] drugs)) (SBAR (WHNP-2 (WDT:[924..928] that)) (S (NP-SBJ-2 (-NONE-:[928..928] *T*)) (VP (VBP:[929..932] are) (VP (VBN:[933..944] metabolised) (NP-2 (-NONE-:[944..944] *)) (PP (IN:[945..947] by) (NP-LGS (NP (NML-1 (NML (NN:[948..958] cytochrome) (NN:[960..964] P450)) (NML (-LRB-:[965..966] -LRB-) (NN:[966..969] CYP) (-RRB-:[969..970] -RRB-))) (CD:[971..972] 1) (NN:[973..975] A2)) (,:[975..976] ,) (NP (NML-1 (-NONE-:[976..976] *P*)) (NN:[977..980] 2A6)) (,:[980..981] ,) (NP (NML-1 (-NONE-:[981..981] *P*)) (NN:[982..985] 2C9)) (,:[985..986] ,) (NP (NML-1 (-NONE-:[986..986] *P*)) (NN:[987..990] 2D6)) (CC:[991..993] or) (NP (NML-1 (-NONE-:[993..993] *P*)) (NN:[994..997] 2E1))))))))))))))))))) (.:[997..998] .))) ;sentence 9 Span:999..1146 ;In drug interaction studies with diazepam, phenytoin and (R)-warfarin, it ;was shown that esomeprazole has the potential to interact with CYP2C19. ;[1002..1006]:substance:"drug" ;[1033..1041]:substance:"diazepam" ;[1043..1052]:substance:"phenytoin" ;[1057..1069]:substance:"(R)-warfarin" ;[1089..1101]:substance:"esomeprazole" ;[1138..1145]:cyp450:"CYP2C19" (SENT (S (PP-LOC (IN:[999..1001] In) (NP (NP (NML (NN:[1002..1006] drug) (NN:[1007..1018] interaction)) (NNS:[1019..1026] studies)) (PP (IN:[1027..1031] with) (NP (NN:[1033..1041] diazepam) (,:[1041..1042] ,) (NN:[1043..1052] phenytoin) (CC:[1053..1056] and) (NN:[1057..1069] -LRB-R-RRB--warfarin))))) (,:[1069..1070] ,) (NP-SBJ-2 (PRP:[1071..1073] it)) (VP (VBD:[1074..1077] was) (VP (VBN:[1078..1083] shown) (NP-2 (-NONE-:[1083..1083] *)) (SBAR (IN:[1084..1088] that) (S (NP-SBJ (NN:[1089..1101] esomeprazole)) (VP (VBZ:[1102..1105] has) (NP (DT:[1106..1109] the) (NN:[1111..1120] potential) (S (NP-SBJ (-NONE-:[1120..1120] *)) (VP (TO:[1121..1123] to) (VP (VB:[1124..1132] interact) (PP-CLR (IN:[1133..1137] with) (NP (NN:[1138..1145] CYP2C19)))))))))))) (.:[1145..1146] .))) ;sentence 10 Span:1147..1307 ;The slightly altered metabolism of cisapride was also suggested to be the ;result of inhibition of a minor metabolic pathway for cisapride mediated by ;CYP2C19. ;[1182..1191]:substance:"cisapride" ;[1277..1286]:substance:"cisapride" ;[1299..1306]:cyp450:"CYP2C19" (SENT (S (NP-SBJ-1 (NP (DT:[1147..1150] The) (ADJP (RB:[1151..1159] slightly) (VBN:[1160..1167] altered)) (NN:[1168..1178] metabolism)) (PP (IN:[1179..1181] of) (NP (NN:[1182..1191] cisapride)))) (VP (VBD:[1193..1196] was) (ADVP (RB:[1197..1201] also)) (VP (VBN:[1202..1211] suggested) (S (NP-SBJ-1 (-NONE-:[1211..1211] *)) (VP (TO:[1212..1214] to) (VP (VB:[1215..1217] be) (NP-PRD (NP (DT:[1218..1221] the) (NN:[1222..1228] result)) (PP (IN:[1229..1231] of) (NP (NP (NN:[1232..1242] inhibition)) (PP (IN:[1243..1245] of) (NP (NP (NP (DT:[1246..1247] a) (JJ:[1248..1253] minor) (JJ:[1254..1263] metabolic) (NN:[1264..1271] pathway)) (PP (IN:[1273..1276] for) (NP (NN:[1277..1286] cisapride)))) (VP (VBN:[1287..1295] mediated) (NP (-NONE-:[1295..1295] *)) (PP (IN:[1296..1298] by) (NP-LGS (NN:[1299..1306] CYP2C19)))))))))))))) (.:[1306..1307] .))) ;sentence 11 Span:1308..1406 ;Esomeprazole did not interact with the CYP3A4 substrates clarithromycin (2 ;studies) or quinidine. ;[1308..1320]:substance:"Esomeprazole" ;[1347..1353]:cyp450:"CYP3A4" ;[1355..1365]:substance:"substrates" ;[1366..1380]:substance:"clarithromycin" ;[1396..1405]:substance:"quinidine" (SENT (S (NP-SBJ (NN:[1308..1320] Esomeprazole)) (VP (VBD:[1321..1324] did) (RB:[1325..1328] not) (VP (VB:[1329..1337] interact) (PP-CLR (IN:[1338..1342] with) (NP (NP (DT:[1343..1346] the) (NN:[1347..1353] CYP3A4) (NNS:[1355..1365] substrates)) (NP (NP (NP (NN:[1366..1380] clarithromycin)) (PRN (-LRB-:[1381..1382] -LRB-) (NP (CD:[1382..1383] 2) (NNS:[1384..1391] studies)) (-RRB-:[1391..1392] -RRB-))) (CC:[1393..1395] or) (NP (NN:[1396..1405] quinidine))))))) (.:[1405..1406] .))) ;sentence 12 Span:1407..1662 ;Since the slightly increased area under the concentration-time curve (AUC) ;of cisapride could be explained as an inhibition of CYP2C19, the data on ;these 3 CYP3A4 substrates indicate that esomeprazole does not have the ;potential to inhibit this enzyme. ;[1486..1495]:substance:"cisapride" ;[1536..1543]:cyp450:"CYP2C19" ;[1565..1571]:cyp450:"CYP3A4" ;[1572..1582]:substance:"substrates" ;[1598..1610]:substance:"esomeprazole" ;[1655..1661]:cyp450:"enzyme" (SENT (S (SBAR-ADV (IN:[1407..1412] Since) (S (NP-SBJ-1 (NP (NP (NP (DT:[1413..1416] the) (ADJP (RB:[1417..1425] slightly) (VBN:[1426..1435] increased)) (NN:[1437..1441] area)) (PP (IN:[1442..1447] under) (NP (DT:[1448..1451] the) (NML (NN:[1452..1465] concentration) (HYPH:[1465..1466] -) (NN:[1466..1470] time)) (NN:[1471..1476] curve)))) (NP (-LRB-:[1477..1478] -LRB-) (NN:[1478..1481] AUC) (-RRB-:[1481..1482] -RRB-))) (PP (IN:[1483..1485] of) (NP (NN:[1486..1495] cisapride)))) (VP (MD:[1496..1501] could) (VP (VB:[1502..1504] be) (VP (VBN:[1505..1514] explained) (NP-1 (-NONE-:[1514..1514] *)) (PP (IN:[1515..1517] as) (NP (NP (DT:[1519..1521] an) (NN:[1522..1532] inhibition)) (PP (IN:[1533..1535] of) (NP (NN:[1536..1543] CYP2C19)))))))))) (,:[1543..1544] ,) (NP-SBJ (NP (DT:[1545..1548] the) (NNS:[1549..1553] data)) (PP (IN:[1554..1556] on) (NP (DT:[1557..1562] these) (CD:[1563..1564] 3) (NN:[1565..1571] CYP3A4) (NNS:[1572..1582] substrates)))) (VP (VBP:[1583..1591] indicate) (SBAR (IN:[1592..1596] that) (S (NP-SBJ (NN:[1598..1610] esomeprazole)) (VP (VBZ:[1611..1615] does) (RB:[1616..1619] not) (VP (VB:[1620..1624] have) (NP (DT:[1625..1628] the) (NN:[1629..1638] potential) (S (NP-SBJ (-NONE-:[1638..1638] *)) (VP (TO:[1639..1641] to) (VP (VB:[1642..1649] inhibit) (NP (DT:[1650..1654] this) (NN:[1655..1661] enzyme))))))))))) (.:[1661..1662] .))) ;sentence 13 Span:1663..1786 ;The minor effects reported for diazepam, phenytoin, (R)-warfarin, and ;cisapride are unlikely to be of clinical relevance. ;[1695..1703]:substance:"diazepam" ;[1705..1714]:substance:"phenytoin" ;[1716..1728]:substance:"(R)-warfarin" ;[1734..1743]:substance:"cisapride" (SENT (S (NP-SBJ-1 (NP (DT:[1663..1666] The) (JJ:[1667..1672] minor) (NNS:[1674..1681] effects)) (VP (VBN:[1682..1690] reported) (NP (-NONE-:[1690..1690] *)) (PP (IN:[1691..1694] for) (NP (NN:[1695..1703] diazepam) (,:[1703..1704] ,) (NN:[1705..1714] phenytoin) (,:[1714..1715] ,) (NN:[1716..1728] -LRB-R-RRB--warfarin) (,:[1728..1729] ,) (CC:[1730..1733] and) (NN:[1734..1743] cisapride))))) (VP (VBP:[1744..1747] are) (ADJP-PRD (JJ:[1749..1757] unlikely) (S (NP-SBJ-1 (-NONE-:[1757..1757] *)) (VP (TO:[1758..1760] to) (VP (VB:[1761..1763] be) (PP-PRD (IN:[1764..1766] of) (NP (JJ:[1767..1775] clinical) (NN:[1776..1785] relevance)))))))) (.:[1785..1786] .))) ;sentence 14 Span:1787..1900 ;Clarithromycin interacts with the metabolism of esomeprazole resulting in a ;doubling of the AUC of esomeprazole. ;[1787..1801]:substance:"Clarithromycin" ;[1836..1848]:substance:"esomeprazole" ;[1887..1899]:substance:"esomeprazole" (SENT (S (NP-SBJ (NN:[1787..1801] Clarithromycin)) (VP (VBZ:[1802..1811] interacts) (PP-CLR (IN:[1812..1816] with) (NP (NP (DT:[1817..1820] the) (NN:[1822..1832] metabolism)) (PP (IN:[1833..1835] of) (NP (NN:[1836..1848] esomeprazole))))) (NP-ADV (NP-SBJ (-NONE-:[1848..1848] *)) (VP (VBG:[1849..1858] resulting) (PP-CLR (IN:[1859..1861] in) (NP (NP (DT:[1862..1863] a) (NN:[1864..1872] doubling)) (PP (IN:[1873..1875] of) (NP (NP (DT:[1876..1879] the) (NN:[1880..1883] AUC)) (PP (IN:[1884..1886] of) (NP (NN:[1887..1899] esomeprazole)))))))))) (.:[1899..1900] .))) ;sentence 15 Span:1902..2000 ;The increased plasma concentrations of esomeprazole are unlikely to have any ;safety implications. ;[1941..1953]:substance:"esomeprazole" (SENT (S (NP-SBJ-1 (NP (DT:[1902..1905] The) (VBN:[1906..1915] increased) (NN:[1916..1922] plasma) (NNS:[1923..1937] concentrations)) (PP (IN:[1938..1940] of) (NP (NN:[1941..1953] esomeprazole)))) (VP (VBP:[1954..1957] are) (ADJP-PRD (JJ:[1958..1966] unlikely) (S (NP-SBJ-1 (-NONE-:[1966..1966] *)) (VP (TO:[1967..1969] to) (VP (VB:[1970..1974] have) (NP (DT:[1975..1978] any) (NN:[1980..1986] safety) (NNS:[1987..1999] implications))))))) (.:[1999..2000] .))) ;sentence 16 Span:2001..2139 ;It can be concluded that the potential for drug-drug interactions with ;esomeprazole is low, and similar to that reported for omeprazole. ;[2044..2048]:substance:"drug" ;[2049..2053]:substance:"drug" ;[2073..2085]:substance:"esomeprazole" ;[2128..2138]:substance:"omeprazole" (SENT (S (NP-SBJ-1 (NP (PRP:[2001..2003] It)) (SBAR-2 (-NONE-:[2003..2003] *ICH*))) (VP (MD:[2004..2007] can) (VP (VB:[2008..2010] be) (VP (VBN:[2011..2020] concluded) (NP-1 (-NONE-:[2020..2020] *)) (SBAR-2 (IN:[2021..2025] that) (S (NP-SBJ (NP (DT:[2026..2029] the) (NN:[2030..2039] potential)) (PP (IN:[2040..2043] for) (NP (NP (NML (NN:[2044..2048] drug) (HYPH:[2048..2049] -) (NN:[2049..2053] drug)) (NNS:[2055..2067] interactions)) (PP (IN:[2068..2072] with) (NP (NN:[2073..2085] esomeprazole)))))) (VP (VBZ:[2086..2088] is) (ADJP-PRD (ADJP (JJ:[2089..2092] low)) (,:[2092..2093] ,) (CC:[2094..2097] and) (ADJP (JJ:[2098..2105] similar) (PP (TO:[2106..2108] to) (NP (NP (DT:[2109..2113] that)) (VP (VBN:[2114..2122] reported) (NP (-NONE-:[2122..2122] *)) (PP (IN:[2123..2126] for) (NP (NN:[2128..2138] omeprazole)))))))))))))) (.:[2138..2139] .))) ;section 17 Span:2143..2161 ;Publication Types: (SEC (FRAG (NNP:[2143..2154] Publication) (NNP:[2155..2160] Types) (::[2160..2161] :))) ;section 18 Span:2167..2173 ;Review (SEC (FRAG (NNP:[2167..2173] Review))) ;section 19 Span:2179..2195 ;Review, Tutorial (SEC (FRAG (NNP:[2179..2185] Review) (,:[2185..2186] ,) (NNP:[2187..2195] Tutorial))) ;section 20 Span:2199..2244 ;PMID: 11510629 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[2199..2203] PMID) (::[2203..2204] :) (CD:[2205..2213] 11510629) (-LRB-:[2214..2215] -LSB-) (NNP:[2215..2221] PubMed) (HYPH:[2222..2223] -) (NN:[2224..2231] indexed) (IN:[2232..2235] for) (NNP:[2236..2243] MEDLINE) (-RRB-:[2243..2244] -RSB-)))